Skip to main content
Premium Trial:

Request an Annual Quote

Michael Deines goes to Dharmacon; Sato to Leave Exelixis for PDL; Zahed Subhan Joins Nuevolution; and Others

NEW YORK, May 7 - Michael Deines is the new vice president of marketing at Dharmacon, the company announced Tuesday.


Deines will lead marketing efforts of the Lafayette, Colo., company's RNA products, including its short interfering RNA (siRNA).


Deines comes to Dharmacon from Sigma-Aldrich, where he was vice president of sales and manager of molecular biology marketing in the biotechnology division. Before joining Sigma-Aldrich, Deines worked in a variety of sales positions at Amersham.



Glen Sato is leaving Exelixis to return to Protein Design Labs as chief financial officer, Exelixis said Tuesday.


Sato is currently senior vice president, chief financial officer, and general counsel of Exelixis. His resignation will be effective in early June, according to the company.  


Before he joined Exelixis three years ago, Sato was vice president, legal and general counsel at Protein Design Labs.


Exelixis said it is  now actively looking for a chief financial officer.



Zahed Subhan has been appointed CEO of Copenhagen-based Nuevolution.


Subhan joins the chemical target-based drug discovery company from Locus Pharmaceuticals, where he held the position of vice president of business development. He previously worked at Sanofi Synthelabo, Glaxo Wellcome, Dupont Merck Pharmaceutical and GeminiGenomics.


Dorothy Wertz, a leading bioethicist at Boston University, died tragically in a scuba-diving accident in Cancun, Mexicoduring the Human Gene Mapping meeting last week. Wertz was slated to speak at the meeting on Global Inequities in Genetics,Wednesday April 30.


In another tragic turn, Kimberly Robart Tau, senior genomics scientist at Covance Central Laboratories, died April 6, according to a report in the Indianapolis Star  Tau, 40, had developed an assay to detect HIV infection as well as a method for freezing and preserving live cells, the paper reported.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.